Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT16 biosimilar to vedolizumab in moderate to severe ulcerative colitis
NCT06570772Phase 3Terminated
- Sponsor
- Alvotech
- Start
- Sep 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of emvistegrast in ulcerative colitis (UC), sponsored by Alvotech. Started Sep 2024; status: terminated.
02
Drugs
emvistegrast
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06570772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06570772.